The η3-allyl–lithium or –potassium compounds [Li{η3-CH(CHSiMe2But)(CHSiMe2R)}(tmen)](R = But 3a, Me 3b) and K{η3-CH(CHSiMe2But)2}(obtained from ButMe2SiCH2CHCHSiMe2R) with ButCN afford the 1-azapentadienyl–lithium or –potassium compounds [Li{η1-N(SiMe2R)C(But)(CH)3SiMe2But}L](L = tmen, R = But 6a, Me 6b; L absent, R = But 8a, Me 8b) or [K{η4-N(SiMe2But)C(But)(CH)3SiMe2But}]∞ 7.
No takes yet. Share an insight, caveat, or question.
Hitchcock et al. (1996) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: